Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.

Name: Αlpha¹ Rigor Record — Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.
Item: Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.
Rating: 100
Author: Αlpha¹

Peng Z, Zhang Y, Xu H, Yang Y, Yang M, Zhang M, Cheng Y, Chen X, Pan Y, Wang F, Li Q, Xu N, Liu L, Gu K, Xiao J, Zhang R, Zhao Q, Chen J, Lin L, Chen Y, Deng Y, Cai S, Bai B, Wang Y, Shen L

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 5★ (Exemplary), 0 critical, 0 high issues for “Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 15, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

5 / 5

Exemplary — no material problems found

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — no deductions. Nothing the checks ran surfaced a material problem.

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Problems surfaced1 type

Overstated conclusions1

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Conclusions only partially backed by the presented evidenceAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted, transparently reported phase 3 randomized trial with a clear scientific premise, rigorous design, and comprehensive reporting of demographics, ethics, resources, statistics, and data availability. The only minor issues are copyedit-level (hyphenation, abbreviation consistency) and the absence of an explicit reporting guideline statement, which do not undermine the scientific integrity.

Both reviewers classified the study as interventional, and this was adopted. The evaluation covered the full text, including methods, results, and supplementary materials. Non-applicable sub-criteria (e.g., animal housing, cell line authentication) were excluded. The statistics verification covered only a subset of tests (2 recomputed consistently); other p-values were not machine-verified. The citation check found no retracted or non-existent references.

4 major claims checked against the paper's own evidence: 1 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Efficacy claim is anchored to an adequate endpoint and a meaningful effect.

Recomputed 2 tests: 2 consistent, 0 inconsistent; 2 via agent-written checks.

Reporting

Eight Dimensions8 pass

The introduction cites prior research on gastric cancer, immunotherapy, and antiangiogenic agents, and acknowledges gaps in knowledge about maintenance strategies. The rationale for comparing the three regimens is clearly linked to the hypothesis that adding apatinib to camrelizumab maintenance may enhance benefit. Limitations of prior research are addressed by designing a phase 3 trial to provide definitive evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for the study.

Evidence

direct quote[Introduction, paragraphs 1-4]

“In a phase 1 study, camrelizumab (a humanised IgG4 monoclonal antibody with high affinity for programmed death 1) combined with apatinib showed encouraging antitumour activity and manageable toxicity in patients with previously treated gastric or gastro-oesophageal junction cancer and hepatocellular carcinoma.”